{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T23:44:53Z","timestamp":1793835893523,"version":"4.6.1"},"reference-count":71,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2015,5,7]],"date-time":"2015-05-07T00:00:00Z","timestamp":1430956800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2015,5,7]],"date-time":"2015-05-07T00:00:00Z","timestamp":1430956800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Malignant pleural mesothelioma (MPM) originates in most of the cases from chronic inflammation of the mesothelium due to exposure to asbestos fibers. Given the limited effect of chemotherapy, a big effort is being made to find new treatment options. The PI3K\/mTOR pathway was reported to be upregulated in MPM. We tested the cell growth inhibition properties of two dual PI3K\/mTOR inhibitors NVP-BEZ235 and GDC-0980 on 19 MPM cell lines. We could identify resistant and sensitive lines; however, there was no correlation to the downregulation of PI3K\/mTOR activity markers. As a result of mTOR inhibition, both drugs efficiently induced long-term autophagy but not cell death. Autophagy blockade by chloroquine in combination with the dual PI3K\/mTOR inhibitors significantly induced caspase-independent cell death involving RIP1 in the sensitive cell line SPC212. Cell death in the resistant cell line Mero-82 was less pronounced, and it was not induced via RIP1-dependent mechanism, suggesting the involvement of RIP1 downstream effectors. Cell death induction was confirmed in 3D systems. Based on these results, we identify autophagy as one of the main mechanisms of cell death resistance against dual PI3K\/mTOR inhibitors in MPM. As PI3K\/mTOR inhibitors are under investigation in clinical trials, these results may help interpreting their outcome and suggest ways for intervention.<\/jats:p>","DOI":"10.1038\/cddis.2015.124","type":"journal-article","created":{"date-parts":[[2015,5,7]],"date-time":"2015-05-07T13:02:17Z","timestamp":1431003737000},"page":"e1757-e1757","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":48,"title":["Inhibition of autophagy sensitizes malignant pleural mesothelioma cells to dual PI3K\/mTOR inhibitors"],"prefix":"10.1038","volume":"6","author":[{"given":"N","family":"Echeverry","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G","family":"Ziltener","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D","family":"Barbone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W","family":"Weder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R A","family":"Stahel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V C","family":"Broaddus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E","family":"Felley-Bosco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,5,7]]},"reference":[{"key":"BFcddis2015124_CR1","doi-asserted-by":"publisher","first-page":"6080","DOI":"10.1038\/sj.onc.1208744","volume":"24","author":"DA Altomare","year":"2005","unstructured":"Altomare DA, You H, Xiao GH, Ramos-Nino ME, Skele KL, De Rienzo A et al. Human and mouse mesotheliomas exhibit elevated AKT\/PKB activity, which can be targeted pharmacologically to inhibit tumor cell growth. Oncogene 2005; 24: 6080\u20136089.","journal-title":"Oncogene"},{"key":"BFcddis2015124_CR2","doi-asserted-by":"publisher","first-page":"3151","DOI":"10.1038\/onc.2013.280","volume":"33","author":"Y Guo","year":"2013","unstructured":"Guo Y, Chirieac LR, Bueno R, Pass H, Wu W, Malinowska IA et al. Tsc1-Tp53 loss induces mesothelioma in mice, and evidence for this mechanism in human mesothelioma. Oncogene 2013; 33: 3151\u20133160.","journal-title":"Oncogene"},{"key":"BFcddis2015124_CR3","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1158\/0008-5472.CAN-14-1008","volume":"75","author":"G Guo","year":"2014","unstructured":"Guo G, Chmielecki J, Goparaju C, Heguy A, Dolgalev I, Carbone M et al. Whole exome sequencing reveals frequent genetic alterations in BAP1, NF2, CDKN2A and CUL1 in malignant pleural mesothelioma. Cancer Res 2014; 75: 264\u2013269.","journal-title":"Cancer Res"},{"key":"BFcddis2015124_CR4","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1038\/ng1975","volume":"39","author":"RK Thomas","year":"2007","unstructured":"Thomas RK, Baker AC, Debiasi RM, Winckler W, Laframboise T, Lin WM et al. High-throughput oncogene mutation profiling in human cancer. Nat Genet 2007; 39: 347\u2013351.","journal-title":"Nat Genet"},{"key":"BFcddis2015124_CR5","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1038\/ng.855","volume":"43","author":"M Bott","year":"2011","unstructured":"Bott M, Brevet M, Taylor BS, Shimizu S, Ito T, Wang L et al. The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma. Nat Genet 2011; 43: 668\u2013672.","journal-title":"Nat Genet"},{"key":"BFcddis2015124_CR6","doi-asserted-by":"publisher","first-page":"4235","DOI":"10.1128\/MCB.01578-08","volume":"29","author":"MA Lopez-Lago","year":"2009","unstructured":"Lopez-Lago MA, Okada T, Murillo MM, Socci N, Giancotti FG . Loss of the tumor suppressor gene NF2, encoding merlin, constitutively activates integrin-dependent mTORC1 signaling. Mol Cell Biol 2009; 29: 4235\u20134249.","journal-title":"Mol Cell Biol"},{"key":"BFcddis2015124_CR7","first-page":"387","volume":"10","author":"LL Garland","year":"2012","unstructured":"Garland LL, Ou SH, Moon J, Mack PC, Testa J, Tsao AS et al. WOG 0722: A phase II study of mTOR inhibitor everolimus (RAD001) in malignant pleural mesothelioma (MPM). J Clin Oncol 2012; 10: 387\u2013391.","journal-title":"J Clin Oncol"},{"key":"BFcddis2015124_CR8","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1158\/0008-5472.CAN-05-2925","volume":"66","author":"KE O'Reilly","year":"2006","unstructured":"O'Reilly KE, Rojo F, She QB, Solit D, Mills GB, Smith D et al. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res 2006; 66: 1500\u20131508.","journal-title":"Cancer Res"},{"key":"BFcddis2015124_CR9","first-page":"3065","volume":"118","author":"A Carracedo","year":"2008","unstructured":"Carracedo A, Ma L, Teruya-Feldstein J, Rojo F, Salmena L, Alimonti A et al. Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. J Clin Invest 2008; 118: 3065\u20133074.","journal-title":"J Clin Invest"},{"key":"BFcddis2015124_CR10","doi-asserted-by":"publisher","first-page":"18200","DOI":"10.1073\/pnas.0405971102","volume":"101","author":"R Rong","year":"2004","unstructured":"Rong R, Tang X, Gutmann DH, Ye K . Neurofibromatosis 2 (NF2) tumor suppressor merlin inhibits phosphatidylinositol 3-kinase through binding to PIKE-L. Proc Natl Acad Sci USA 2004; 101: 18200\u201318205.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFcddis2015124_CR11","first-page":"471","volume":"6","author":"AM Petrilli","year":"2014","unstructured":"Petrilli AM, Fuse MA, Donnan MS, Bott M, Sparrow NA, Tondera D et al. A chemical biology approach identified PI3K as a potential therapeutic target for neurofibromatosis type 2. Am J Transl Res 2014; 6: 471\u2013493.","journal-title":"Am J Transl Res"},{"key":"BFcddis2015124_CR12","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1038\/nature11005","volume":"483","author":"MJ Garnett","year":"2012","unstructured":"Garnett MJ, Edelman EJ, Heidorn SJ, Greenman CD, Dastur A, Lau KW et al. Systematic identification of genomic markers of drug sensitivity in cancer cells. Nature 2012; 483: 570\u2013575.","journal-title":"Nature"},{"key":"BFcddis2015124_CR13","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.lungcan.2012.02.022","volume":"77","author":"S Cedres","year":"2012","unstructured":"Cedres S, Montero MA, Martinez P, Martinez A, Rodriguez-Freixinos V, Torrejon D et al. Exploratory analysis of activation of PTEN-PI3K pathway and downstream proteins in malignant pleural mesothelioma (MPM). Lung Cancer 2012; 77: 192\u2013198.","journal-title":"Lung Cancer"},{"key":"BFcddis2015124_CR14","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1097\/JTO.0000000000000055","volume":"9","author":"BK Bitanihirwe","year":"2014","unstructured":"Bitanihirwe BK, Meerang M, Friess M, Soltermann A, Frischknecht L, Thies S et al. PI3K\/mTOR signaling in mesothelioma patients treated with induction chemotherapy followed by extrapleural pneumonectomy. J Thorac Oncol 2014; 9: 239\u2013247.","journal-title":"J Thorac Oncol"},{"key":"BFcddis2015124_CR15","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.1158\/1535-7163.MCT-08-0017","volume":"7","author":"SM Maira","year":"2008","unstructured":"Maira SM, Stauffer F, Brueggen J, Furet P, Schnell C, Fritsch C et al. Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase\/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity. Mol Cancer Ther 2008; 7: 1851\u20131863.","journal-title":"Mol Cancer Ther"},{"key":"BFcddis2015124_CR16","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.1124\/dmd.112.046052","volume":"40","author":"L Salphati","year":"2012","unstructured":"Salphati L, Pang J, Plise EG, Lee LB, Olivero AG, Prior WW et al. Preclinical assessment of the absorption and disposition of the phosphatidylinositol 3-kinase\/mammalian target of rapamycin inhibitor GDC-0980 and prediction of its pharmacokinetics and efficacy in human. Drug Metab Dispos 2012; 40: 1785\u20131796.","journal-title":"Drug Metab Dispos"},{"key":"BFcddis2015124_CR17","volume-title":"Evaluation of Tolerability and Anti-tumor Activity of GDC-0980, an Oral PI3K\/mTOR Inhibitor, Administered to Patients with Advanced Solid Tumors or Non-Hodgkin's Lymphoma. ECCO-ESMO-ESTRO 2013","author":"S Dolly","year":"2013","unstructured":"Dolly S, Bendell JC, Kindler H, Lauchle JO, Krug LM, Seiwert TY et al Evaluation of Tolerability and Anti-tumor Activity of GDC-0980, an Oral PI3K\/mTOR Inhibitor, Administered to Patients with Advanced Solid Tumors or Non-Hodgkin's Lymphoma. ECCO-ESMO-ESTRO 2013. EJC: Amsterdam, The Netherlands, 2013."},{"key":"BFcddis2015124_CR18","doi-asserted-by":"crossref","unstructured":"Makker V, Recio FO, Ma L, Matulonis U, O'Hara Lauchle J, Parmar H et al. Phase II trial of GDC-0980 (dual PI3K\/mTOR inhibitor) in patients with advanced endometrial carcinoma: final study results. J Clin Oncol 2014. (abstract 5513).","DOI":"10.1200\/jco.2014.32.15_suppl.5513"},{"key":"BFcddis2015124_CR19","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.lungcan.2012.07.005","volume":"78","author":"B Fischer","year":"2012","unstructured":"Fischer B, Frei C, Moura U, Stahel R, Felley-Bosco E . Inhibition of phosphoinositide-3 kinase pathway down regulates ABCG2 function and sensitizes malignant pleural mesothelioma to chemotherapy. Lung Cancer 2012; 78: 23\u201329.","journal-title":"Lung Cancer"},{"key":"BFcddis2015124_CR20","doi-asserted-by":"publisher","first-page":"22299","DOI":"10.1073\/pnas.0905152106","volume":"106","author":"SM Brachmann","year":"2009","unstructured":"Brachmann SM, Hofmann I, Schnell C, Fritsch C, Wee S, Lane H et al. Specific apoptosis induction by the dual PI3K\/mTor inhibitor NVP-BEZ235 in HER2 amplified and PIK3CA mutant breast cancer cells. Proc Natl Acad Sci USA 2009; 106: 22299\u201322304.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFcddis2015124_CR21","doi-asserted-by":"publisher","first-page":"8022","DOI":"10.1158\/0008-5472.CAN-08-1385","volume":"68","author":"V Serra","year":"2008","unstructured":"Serra V, Markman B, Scaltriti M, Eichhorn PJ, Valero V, Guzman M et al. NVP-BEZ235, a dual PI3K\/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations. Cancer Res 2008; 68: 8022\u20138030.","journal-title":"Cancer Res"},{"key":"BFcddis2015124_CR22","doi-asserted-by":"publisher","first-page":"2426","DOI":"10.1158\/1535-7163.MCT-11-0446","volume":"10","author":"JJ Wallin","year":"2011","unstructured":"Wallin JJ, Edgar KA, Guan J, Berry M, Prior WW, Lee L et al. GDC-0980 is a novel class I PI3K\/mTOR kinase inhibitor with robust activity in cancer models driven by the PI3K pathway. Mol Cancer Ther 2011; 10: 2426\u20132436.","journal-title":"Mol Cancer Ther"},{"key":"BFcddis2015124_CR23","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1158\/1535-7163.MCT-11-0530","volume":"11","author":"PB Bitterman","year":"2012","unstructured":"Bitterman PB, Polunovsky VA . Attacking a nexus of the oncogenic circuitry by reversing aberrant eIF4F-mediated translation. Mol Cancer Ther 2012; 11: 1051\u20131061.","journal-title":"Mol Cancer Ther"},{"key":"BFcddis2015124_CR24","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1111\/j.1349-7006.2006.00184.x","volume":"97","author":"N Usami","year":"2006","unstructured":"Usami N, Fukui T, Kondo M, Taniguchi T, Yokoyama T, Mori S et al. Establishment and characterization of four malignant pleural mesothelioma cell lines from Japanese patients. Cancer Sci 2006; 97: 387\u2013394.","journal-title":"Cancer Sci"},{"key":"BFcddis2015124_CR25","doi-asserted-by":"crossref","unstructured":"Shapiro IM, Kolev VN, Vidal CM, Kadariya Y, Ring JE, Wright Q et al. Merlin deficiency predicts FAK inhibitor sensitivity: a synthetic lethal relationship. Sci Transl Med 2014; 6 237ra68.","DOI":"10.1126\/scitranslmed.3008639"},{"key":"BFcddis2015124_CR26","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1038\/nature11003","volume":"483","author":"J Barretina","year":"2012","unstructured":"Barretina J, Caponigro G, Stransky N, Venkatesan K, Margolin AA, Kim S et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 2012; 483: 603\u2013607.","journal-title":"Nature"},{"key":"BFcddis2015124_CR27","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1038\/nrm2708","volume":"10","author":"H Nakatogawa","year":"2009","unstructured":"Nakatogawa H, Suzuki K, Kamada Y, Ohsumi Y . Dynamics and diversity in autophagy mechanisms: lessons from yeast. Nat Rev Mol Cell Biol 2009; 10: 458\u2013467.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"BFcddis2015124_CR28","doi-asserted-by":"publisher","first-page":"e892","DOI":"10.1038\/cddis.2013.422","volume":"4","author":"B Liu","year":"2013","unstructured":"Liu B, Wen X, Cheng Y . Survival or death: disequilibrating the oncogenic and tumor suppressive autophagy in cancer. Cell Death Dis 2013; 4: e892.","journal-title":"Cell Death Dis"},{"key":"BFcddis2015124_CR29","doi-asserted-by":"publisher","first-page":"2204","DOI":"10.1158\/1535-7163.MCT-09-0160","volume":"8","author":"TJ Liu","year":"2009","unstructured":"Liu TJ, Koul D, LaFortune T, Tiao N, Shen RJ, Maira SM et al. NVP-BEZ235, a novel dual phosphatidylinositol 3-kinase\/mammalian target of rapamycin inhibitor, elicits multifaceted antitumor activities in human gliomas. Mol Cancer Ther 2009; 8: 2204\u20132210.","journal-title":"Mol Cancer Ther"},{"key":"BFcddis2015124_CR30","doi-asserted-by":"publisher","first-page":"ra81","DOI":"10.1126\/scisignal.2001017","volume":"3","author":"QW Fan","year":"2010","unstructured":"Fan QW, Cheng C, Hackett C, Feldman M, Houseman BT, Nicolaides T et al. Akt and autophagy cooperate to promote survival of drug-resistant glioma. Sci Signal 2010; 3: ra81.","journal-title":"Sci Signal"},{"key":"BFcddis2015124_CR31","doi-asserted-by":"publisher","first-page":"1230","DOI":"10.1124\/mol.112.080408","volume":"82","author":"GJ Cerniglia","year":"2012","unstructured":"Cerniglia GJ, Karar J, Tyagi S, Christofidou-Solomidou M, Rengan R, Koumenis C et al. Inhibition of autophagy as a strategy to augment radiosensitization by the dual phosphatidylinositol 3-kinase\/mammalian target of rapamycin inhibitor NVP-BEZ235. Mol Pharmacol 2012; 82: 1230\u20131240.","journal-title":"Mol Pharmacol"},{"key":"BFcddis2015124_CR32","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1016\/j.bbrc.2014.09.115","volume":"453","author":"JY Tang","year":"2014","unstructured":"Tang JY, Dai T, Zhang H, Xiong WJ, Xu MZ, Wang XJ et al. GDC-0980-induced apoptosis is enhanced by autophagy inhibition in human pancreatic cancer cells. Biochem Biophys Res Commun 2014; 453: 533\u2013538.","journal-title":"Biochem Biophys Res Commun"},{"key":"BFcddis2015124_CR33","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1186\/1471-2407-12-571","volume":"12","author":"Y Shi","year":"2012","unstructured":"Shi Y, Felley-Bosco E, Marti TM, Orlowski K, Pruschy M, Stahel RA . Starvation-induced activation of ATM\/Chk2\/p53 signaling sensitizes cancer cells to cisplatin. BMC Cancer 2012; 12: 571.","journal-title":"BMC Cancer"},{"key":"BFcddis2015124_CR34","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1007\/s10549-010-1232-1","volume":"129","author":"C Brunner-Kubath","year":"2011","unstructured":"Brunner-Kubath C, Shabbir W, Saferding V, Wagner R, Singer CF, Valent P et al. The PI3 kinase\/mTOR blocker NVP-BEZ235 overrides resistance against irreversible ErbB inhibitors in breast cancer cells. Breast Cancer Res Treat 2011; 129: 387\u2013400.","journal-title":"Breast Cancer Res Treat"},{"key":"BFcddis2015124_CR35","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1158\/1078-0432.CCR-09-0816","volume":"16","author":"MC Manara","year":"2010","unstructured":"Manara MC, Nicoletti G, Zambelli D, Ventura S, Guerzoni C, Landuzzi L et al. NVP-BEZ235 as a new therapeutic option for sarcomas. Clin Cancer Res 2010; 16: 530\u2013540.","journal-title":"Clin Cancer Res"},{"key":"BFcddis2015124_CR36","doi-asserted-by":"publisher","first-page":"8097","DOI":"10.1158\/0008-5472.CAN-10-1814","volume":"70","author":"F Chiarini","year":"2010","unstructured":"Chiarini F, Grimaldi C, Ricci F, Tazzari PL, Evangelisti C, Ognibene A et al. Activity of the novel dual phosphatidylinositol 3-kinase\/mammalian target of rapamycin inhibitor NVP-BEZ235 against T-cell acute lymphoblastic leukemia. Cancer Res 2010; 70: 8097\u20138107.","journal-title":"Cancer Res"},{"key":"BFcddis2015124_CR37","doi-asserted-by":"publisher","first-page":"e41831","DOI":"10.1371\/journal.pone.0041831","volume":"7","author":"K Bray","year":"2012","unstructured":"Bray K, Mathew R, Lau A, Kamphorst JJ, Fan J, Chen J et al. Autophagy suppresses RIP kinase-dependent necrosis enabling survival to mTOR inhibition. PLoS One 2012; 7: e41831.","journal-title":"PLoS One"},{"key":"BFcddis2015124_CR38","doi-asserted-by":"publisher","first-page":"2682","DOI":"10.1002\/ijc.27935","volume":"132","author":"C Seitz","year":"2013","unstructured":"Seitz C, Hugle M, Cristofanon S, Tchoghandjian A, Fulda S . The dual PI3K\/mTOR inhibitor NVP-BEZ235 and chloroquine synergize to trigger apoptosis via mitochondrial-lysosomal cross-talk. Int J Cancer 2013; 132: 2682\u20132693.","journal-title":"Int J Cancer"},{"key":"BFcddis2015124_CR39","doi-asserted-by":"publisher","first-page":"549","DOI":"10.4161\/cbt.12.6.16397","volume":"12","author":"CX Xu","year":"2011","unstructured":"Xu CX, Zhao L, Yue P, Fang G, Tao H, Owonikoko TK et al. Augmentation of NVP-BEZ235's anticancer activity against human lung cancer cells by blockage of autophagy. Cancer Biol Ther 2011; 12: 549\u2013555.","journal-title":"Cancer Biol Ther"},{"key":"BFcddis2015124_CR40","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1083\/jcb.90.3.665","volume":"90","author":"B Poole","year":"1981","unstructured":"Poole B, Ohkuma S . Effect of weak bases on the intralysosomal pH in mouse peritoneal macrophages. J Cell Biol 1981; 90: 665\u2013669.","journal-title":"J Cell Biol"},{"key":"BFcddis2015124_CR41","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1038\/cdd.2014.137","volume":"22","author":"L Galluzzi","year":"2014","unstructured":"Galluzzi L, Bravo-San Pedro JM, Vitale I, Aaronson SA, Abrams JM, Adam D et al. Essential versus accessory aspects of cell death: recommendations of the NCCD 2015. Cell Death Differ 2014; 22: 58\u201373.","journal-title":"Cell Death Differ"},{"key":"BFcddis2015124_CR42","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1038\/nchembio.83","volume":"4","author":"A Degterev","year":"2008","unstructured":"Degterev A, Hitomi J, Germscheid M, Ch'en IL, Korkina O, Teng X et al. Identification of RIP1 kinase as a specific cellular target of necrostatins. Nat Chem Biol 2008; 4: 313\u2013321.","journal-title":"Nat Chem Biol"},{"key":"BFcddis2015124_CR43","doi-asserted-by":"publisher","first-page":"S17","DOI":"10.1517\/14728222.2011.639361","volume":"16","author":"A De Luca","year":"2012","unstructured":"De Luca A, Maiello MR, D'Alessio A, Pergameno M, Normanno N . The RAS\/RAF\/MEK\/ERK and the PI3K\/AKT signalling pathways: role in cancer pathogenesis and implications for therapeutic approaches. Expert Opin Ther Targets 2012; 16: S17\u2013S27.","journal-title":"Expert Opin Ther Targets"},{"key":"BFcddis2015124_CR44","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1038\/cdd.2009.32","volume":"16","author":"J Daubriac","year":"2009","unstructured":"Daubriac J, Fleury-Feith J, Kheuang L, Galipon J, Saint-Albin A, Renier A et al. Malignant pleural mesothelioma cells resist anoikis as quiescent pluricellular aggregates. Cell Death Differ 2009; 16: 1146\u20131155.","journal-title":"Cell Death Differ"},{"key":"BFcddis2015124_CR45","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1165\/rcmb.2004-0355OC","volume":"33","author":"KU Kim","year":"2005","unstructured":"Kim KU, Wilson SM, Abayasiriwardana KS, Collins R, Fjellbirkeland L, Xu Z et al. A novel in vitro model of human mesothelioma for studying tumor biology and apoptotic resistance. Am J Respir Cell Mol Biol 2005; 33: 541\u2013548.","journal-title":"Am J Respir Cell Mol Biol"},{"key":"BFcddis2015124_CR46","doi-asserted-by":"publisher","first-page":"e174","DOI":"10.1038\/cddis.2011.58","volume":"2","author":"D Barbone","year":"2011","unstructured":"Barbone D, Ryan JA, Kolhatkar N, Chacko AD, Jablons DM, Sugarbaker DJ et al. The Bcl-2 repertoire of mesothelioma spheroids underlies acquired apoptotic multicellular resistance. Cell Death Dis 2011; 2: e174.","journal-title":"Cell Death Dis"},{"key":"BFcddis2015124_CR47","doi-asserted-by":"publisher","first-page":"13021","DOI":"10.1074\/jbc.M709698200","volume":"283","author":"D Barbone","year":"2008","unstructured":"Barbone D, Yang TM, Morgan JR, Gaudino G, Broaddus VC . Mammalian target of rapamycin contributes to the acquired apoptotic resistance of human mesothelioma multicellular spheroids. J Biol Chem 2008; 283: 13021\u201313030.","journal-title":"J Biol Chem"},{"key":"BFcddis2015124_CR48","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1038\/nprot.2008.226","volume":"4","author":"J Friedrich","year":"2009","unstructured":"Friedrich J, Seidel C, Ebner R, Kunz-Schughart LA . Spheroid-based drug screen: considerations and practical approach. Nat Protoc 2009; 4: 309\u2013324.","journal-title":"Nat Protoc"},{"key":"BFcddis2015124_CR49","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1038\/modpathol.2011.146","volume":"25","author":"K Kadota","year":"2012","unstructured":"Kadota K, Suzuki K, Colovos C, Sima CS, Rusch VW, Travis WD et al. A nuclear grading system is a strong predictor of survival in epitheloid diffuse malignant pleural mesothelioma. Mod Pathol 2012; 25: 260\u2013271.","journal-title":"Mod Pathol"},{"key":"BFcddis2015124_CR50","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1016\/j.ccr.2012.10.023","volume":"22","author":"A Britschgi","year":"2012","unstructured":"Britschgi A, Andraos R, Brinkhaus H, Klebba I, Romanet V, Muller U et al. JAK2\/STAT5 inhibition circumvents resistance to PI3K\/mTOR blockade: a rationale for cotargeting these pathways in metastatic breast cancer. Cancer Cell 2012; 22: 796\u2013811.","journal-title":"Cancer Cell"},{"key":"BFcddis2015124_CR51","doi-asserted-by":"publisher","first-page":"e105919","DOI":"10.1371\/journal.pone.0105919","volume":"9","author":"R Kanteti","year":"2014","unstructured":"Kanteti R, Dhanasingh I, Kawada I, Lennon FE, Arif Q, Bueno R et al. MET and PI3K\/mTOR as a potential combinatorial therapeutic target in malignant pleural mesothelioma. PLoS One 2014; 9: e105919.","journal-title":"PLoS One"},{"key":"BFcddis2015124_CR52","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1158\/1535-7163.MCT-14-0669","volume":"14","author":"HP Soares","year":"2015","unstructured":"Soares HP, Ming M, Mellon M, Young SH, Han L, Sinnet-Smith J et al. Dual PI3K\/mTOR inhibitors induce rapid over-activation of the MEK\/ERK pathway in human pancreatic cancer cells through suppression of mTORC2. Mol Cancer Ther 2015; 14: 1014\u20131023.","journal-title":"Mol Cancer Ther"},{"key":"BFcddis2015124_CR53","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1158\/2159-8290.CD-13-0063","volume":"3","author":"SJ Klempner","year":"2013","unstructured":"Klempner SJ, Myers AP, Cantley LC . What a tangled web we weave: emerging resistance mechanisms to inhibition of the phosphoinositide 3-kinase pathway. Cancer Discov 2013; 3: 1345\u20131354.","journal-title":"Cancer Discov"},{"key":"BFcddis2015124_CR54","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/j.ccr.2011.12.024","volume":"21","author":"T Muranen","year":"2012","unstructured":"Muranen T, Selfors LM, Worster DT, Iwanicki MP, Song L, Morales FC et al. Inhibition of PI3K\/mTOR leads to adaptive resistance in matrix-attached cancer cells. Cancer Cell 2012; 21: 227\u2013239.","journal-title":"Cancer Cell"},{"key":"BFcddis2015124_CR55","doi-asserted-by":"publisher","first-page":"4665","DOI":"10.1093\/nar\/gkq241","volume":"38","author":"A Riley","year":"2010","unstructured":"Riley A, Jordan LE, Holcik M . Distinct 5' UTRs regulate XIAP expression under normal growth conditions and during cellular stress. Nucleic Acids Res 2010; 38: 4665\u20134674.","journal-title":"Nucleic Acids Res"},{"key":"BFcddis2015124_CR56","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1038\/35080103","volume":"2","author":"M Holcik","year":"2001","unstructured":"Holcik M, Korneluk RG . XIAP the guardian angel. Nat Rev Mol Cell Biol 2001; 2: 550\u2013556.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"BFcddis2015124_CR57","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/j.molcel.2009.01.021","volume":"33","author":"VI Korolchuk","year":"2009","unstructured":"Korolchuk VI, Mansilla A, Menzies FM, Rubinsztein DC . Autophagy inhibition compromises degradation of ubiquitin-proteasome pathway substrates. Mol Cell 2009; 33: 517\u2013527.","journal-title":"Mol Cell"},{"key":"BFcddis2015124_CR58","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1016\/j.cmet.2007.11.004","volume":"6","author":"J Zhao","year":"2007","unstructured":"Zhao J, Brault JJ, Schild A, Cao P, Sandri M, Schiaffino S et al. FoxO3 coordinately activates protein degradation by the autophagic\/lysosomal and proteasomal pathways in atrophying muscle cells. Cell Metab 2007; 6: 472\u2013483.","journal-title":"Cell Metab"},{"key":"BFcddis2015124_CR59","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1007\/s00109-011-0774-y","volume":"89","author":"OK Mirzoeva","year":"2011","unstructured":"Mirzoeva OK, Hann B, Hom YK, Debnath J, Aftab D, Shokat K et al. Autophagy suppression promotes apoptotic cell death in response to inhibition of the PI3K-mTOR pathway in pancreatic adenocarcinoma. J Mol Med 2011; 89: 877\u2013889.","journal-title":"J Mol Med"},{"key":"BFcddis2015124_CR60","doi-asserted-by":"publisher","first-page":"1758","DOI":"10.1158\/1535-7163.MCT-12-0015","volume":"11","author":"MP Ghadimi","year":"2012","unstructured":"Ghadimi MP, Lopez G, Torres KE, Belousov R, Young ED, Liu J et al. Targeting the PI3K\/mTOR axis, alone and in combination with autophagy blockade, for the treatment of malignant peripheral nerve sheath tumors. Mol Cancer Ther 2012; 11: 1758\u20131769.","journal-title":"Mol Cancer Ther"},{"key":"BFcddis2015124_CR61","doi-asserted-by":"publisher","first-page":"1796","DOI":"10.1016\/j.celrep.2014.05.008","volume":"7","author":"M Yabal","year":"2014","unstructured":"Yabal M, Muller N, Adler H, Knies N, Gross CJ, Damgaard RB et al. XIAP restricts TNF- and RIP3-dependent cell death and inflammasome activation. Cell Rep 2014; 7: 1796\u20131808.","journal-title":"Cell Rep"},{"key":"BFcddis2015124_CR62","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.cell.2004.11.046","volume":"120","author":"JJ Lum","year":"2005","unstructured":"Lum JJ, Bauer DE, Kong M, Harris MH, Li C, Lindsten T et al. Growth factor regulation of autophagy and cell survival in the absence of apoptosis. Cell 2005; 120: 237\u2013248.","journal-title":"Cell"},{"key":"BFcddis2015124_CR63","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.ccr.2014.06.025","volume":"26","author":"H Maes","year":"2014","unstructured":"Maes H, Kuchnio A, Peric A, Moens S, Nys K, De Bock K et al. Tumor vessel normalization by chloroquine independent of autophagy. Cancer Cell 2014; 26: 190\u2013206.","journal-title":"Cancer Cell"},{"key":"BFcddis2015124_CR64","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1038\/nrc3262","volume":"12","author":"E White","year":"2012","unstructured":"White E . Deconvoluting the context-dependent role for autophagy in cancer. Nat Rev Cancer 2012; 12: 401\u2013410.","journal-title":"Nat Rev Cancer"},{"key":"BFcddis2015124_CR65","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1016\/j.cell.2013.11.019","volume":"155","author":"JY Guo","year":"2013","unstructured":"Guo JY, Xia B, White E . Autophagy-mediated tumor promotion. Cell 2013; 155: 1216\u20131219.","journal-title":"Cell"},{"key":"BFcddis2015124_CR66","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1002\/jcb.240630505","volume":"24","author":"RM Phelps","year":"1996","unstructured":"Phelps RM, Johnson BE, Ihde DC, Gazdar AF, Carbone DP, McClintock PR et al. NCI-Navy Medical Oncology Branch cell line data base. J Cell Biochem Suppl 1996; 24: 32\u201391.","journal-title":"J Cell Biochem Suppl"},{"key":"BFcddis2015124_CR67","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1007\/0-306-46872-7_4","volume-title":"Human Cell Culture","author":"MA Versnel","year":"2002","unstructured":"Versnel MA . Mesothelioma. In: Masters JR, Palson B (eds). Human Cell Culture. Springer: The Netherlands, 2002, pp 87\u2013106."},{"key":"BFcddis2015124_CR68","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1002\/ijc.2910470219","volume":"47","author":"LS Manning","year":"1991","unstructured":"Manning LS, Whitaker D, Murch AR, Garlepp MJ, Davis MR, Musk AW et al. Establishment and characterization of five human malignant mesothelioma cell lines derived from pleural effusions. Int J Cancer 1991; 47: 285\u2013290.","journal-title":"Int J Cancer"},{"key":"BFcddis2015124_CR69","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1593\/neo.11828","volume":"13","author":"PA Knobel","year":"2011","unstructured":"Knobel PA, Kotov IN, Felley-Bosco E, Stahel RA, Marti TM . Inhibition of REV3 expression induces persistent DNA damage and growth arrest in cancer cells. Neoplasia 2011; 13: 961\u2013970.","journal-title":"Neoplasia"},{"key":"BFcddis2015124_CR70","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.lungcan.2008.08.014","volume":"64","author":"C Thurneysen","year":"2009","unstructured":"Thurneysen C, Opitz I, Kurtz S, Weder W, Stahel RA, Felley-Bosco E . Functional inactivation of NF2\/merlin in human mesothelioma. Lung Cancer 2009; 64: 140\u2013147.","journal-title":"Lung Cancer"},{"key":"BFcddis2015124_CR71","doi-asserted-by":"publisher","first-page":"202ra123","DOI":"10.1126\/scitranslmed.3005864","volume":"5","author":"H Liu","year":"2013","unstructured":"Liu H, He Z, von Rutte T, Yousefi S, Hunger RE, Simon HU . Down-regulation of autophagy-related protein 5 (ATG5) contributes to the pathogenesis of early-stage cutaneous melanoma. Sci Transl Med 2013; 5: 202ra123.","journal-title":"Sci Transl Med"}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/cddis2015124.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/cddis2015124","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/cddis2015124.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,5]],"date-time":"2023-01-05T10:02:02Z","timestamp":1672912922000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/cddis2015124"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,5,7]]},"references-count":71,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2015,5]]}},"alternative-id":["BFcddis2015124"],"URL":"https:\/\/doi.org\/10.1038\/cddis.2015.124","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,5,7]]},"assertion":[{"value":"21 January 2015","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 March 2015","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 March 2015","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 May 2015","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}